HEALTH TIPS.: The FDA’s weak drug manufacturing oversight is a potentially deadly problem: COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.

Tuesday, 27 July 2021

The FDA’s weak drug manufacturing oversight is a potentially deadly problem: COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.

The FDA’s weak drug manufacturing oversight is a potentially deadly problem: COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.

submitted by /u/shallah
[link] [comments]

from Health https://ift.tt/3iPeOjq
via IFTTT

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)